Foundational Principles: Epidemiology, Pathophysiology & Risk Factors

I. Epidemiology & Incidence

SSTIs have steadily increased in frequency and severity, driven by community-associated MRSA and rising comorbid disease. Although acute osteomyelitis is less common, critical care admissions carry high morbidity.

• Rising SSTI admissions: A nearly 30% increase in U.S. hospitalizations was observed from 2000–2004.
• Community-associated MRSA (CA-MRSA): Now accounts for a large share of purulent SSTIs in both outpatient and inpatient settings.
• Necrotizing soft-tissue infections (NSTIs): Comprise approximately 0.2–1.2% of ICU admissions, with an associated ICU mortality of 20–30%.
• Acute osteomyelitis: Represents 5–10% of bone infections in tertiary centers. MRSA is implicated in about 40% of cases that require ICU care.

Impact of Comorbidities

• Diabetes mellitus: Impaired neutrophil function and microvascular disease contribute to the progression of 10–20% of foot ulcers to osteomyelitis. Glycemic control (HbA1c <7%) is key to reducing recurrence.
• Peripheral vascular disease & neuropathy: These conditions lead to delayed presentation and encourage polymicrobial flora, including gram-negatives and anaerobes.
• Immunocompromised states (neutropenia, HIV): These states are associated with a broadened pathogen spectrum and atypical presentations, necessitating early biopsy and broad empiric coverage.

II. Pathophysiology

SSTIs range from superficial dermal invasion (cellulitis) to deep fascial necrosis (NSTI) and bone infection (osteomyelitis), each with distinct host-pathogen interactions.

A. Cellulitis

Cellulitis is an infection of the dermis and subcutaneous tissue, typically caused by Staphylococcus aureus and Streptococcus pyogenes. The clinical hallmark is non-purulent erythema with advancing borders. In the ICU, associated capillary leak can complicate fluid management.

B. Necrotizing Fasciitis (NSTI)

NSTI is a rapidly progressing infection of the superficial and deep fascia. It is characterized by microvascular thrombosis from bacterial toxins, which leads to tissue hypoxia, accelerated necrosis, and impaired antibiotic delivery. Urgent surgical debridement within 6–12 hours is critical to reduce mortality. Treatment includes broad-spectrum antibiotics, often with clindamycin for toxin suppression.

• Type I (Polymicrobial): Caused by a mix of anaerobes and gram-negatives, often generating gas in the tissues.
• Type II (Monomicrobial): Usually caused by Group A Streptococcus (GAS), which produces potent exotoxins (e.g., SPE B) that cleave fascial planes.

C. Osteomyelitis

Osteomyelitis is an infection of the bone, most commonly caused by S. aureus (both MSSA and MRSA). Chronic cases, especially in diabetic foot infections, often involve mixed flora.

• Hematogenous Spread: Bacteria lodge in metaphyseal capillary loops. The resulting inflammatory exudate increases intramedullary pressure, causing endosteal ischemia and bone necrosis (sequestrum).
• Contiguous Spread: Infection spreads from an adjacent SSTI, trauma, or prosthetic implant. Biofilm formation on hardware is a major challenge, protecting pathogens from antibiotics and host defenses.

III. Risk Factors

Host comorbidities, immunosuppressive therapies, and iatrogenic exposures significantly elevate the risk for SSTIs and osteomyelitis.

A. Chronic Diseases

• Diabetes mellitus: Hyperglycemia impairs neutrophil function, while microvascular disease limits antibiotic penetration into tissues.
• Peripheral vascular disease & neuropathy: Contribute to delayed wound detection and create an environment for polymicrobial infections.
• Smoking, malnutrition, chronic alcohol use: These factors lead to vasoconstriction, poor leukocyte function, and disruption of the gut barrier.

B. Immunosuppression

• Neutropenia (ANC < 500/µL): Increases risk of fungal and gram-negative SSTIs. Empiric antifungal or anti-pseudomonal coverage is warranted in cases of hemodynamic instability.
• Steroid therapy and biologics: Diminish macrophage and T-cell function, allowing for deeper tissue invasion by pathogens.
• HIV (CD4 < 200 cells/µL), malignancy, post-transplant states: Associated with a broadened list of potential pathogens (e.g., Nocardia, Cryptococcus) and often muted inflammatory signs.

C. Iatrogenic & Environmental

• Trauma, surgery, indwelling devices: Provide direct portals for infection and promote biofilm formation on implants.
• Hygiene and socioeconomic barriers: Overcrowding and limited access to follow-up care can lead to delayed presentation and treatment failure.

IV. Social Determinants of Health

Non-medical factors, including socioeconomic conditions and access to healthcare, significantly influence infection risk, treatment adherence, and patient outcomes.

• Access to care: Delays greater than 6 hours to the first antibiotic dose in NSTI are associated with increased mortality. Limited outpatient resources can hinder early intervention for less severe infections.
• Health literacy & adherence: A poor understanding of wound care instructions and antibiotic regimens can lead to recurrence. Tailored patient education and simplified regimens are proven to improve outcomes.
• Socioeconomic status: Factors like homelessness, food insecurity, and lack of refrigeration for medications can impede outpatient parenteral antibiotic therapy (OPAT). Multidisciplinary support has been shown to reduce readmissions by approximately 25%.